Is Your AREDS Formula Actually Enough?
If you take a daily AREDS formula and your central vision keeps getting worse at every exam — blurrier chart, new distortions, another small change — it isn't your fault. The truth is simpler, and harder: the formula itself is built on 1996 science — and it was never designed to cover what we now know drives macular decline.
It's a quiet question that tends to surface in the waiting room, somewhere between the eye drops and the next appointment card: you've been taking it faithfully — so why does the chart keep moving the wrong way?
Here's the part almost no one says out loud. The AREDS protocol was designed around research that began in the early 1990s and was finalized in 1996. We are now in 2026. In those three decades, hundreds of new studies have reshaped what scientists understand about age-related vision decline — how the macula actually breaks down, which nutrients reach it, and which ones the original formula completely left out.
So if you've been doing everything right and your eyes are still changing, the issue isn't your discipline. It's the formula. AREDS was a real step forward — for its time. But it's a six-ingredient answer to a problem we now know has three root causes and a much richer list of nutrients behind it. There are better tools now. The rest of this page is about what changed — and what a 2026-grade formula actually looks like.
You Did Everything Right. The Formula Did Less Than You Were Told.
You took it every single day. Exactly the way your ophthalmologist recommended it, year after year, without missing a dose. And still — at each annual exam — the chart showed another small change. If that's your story, hear this clearly: that is not a personal failure.
Here's the part the brochures tend to underplay. In the landmark trial, the original formula was shown to reduce the risk of progression to advanced AMD by about a quarter in higher-risk patients (AREDS Research Group, 2001). That was a genuine, important result. But read it the other way around, the way the math actually works: a benefit "for about a quarter" means most people still saw their eyes change over time.
So the quiet feeling you've been carrying — "I did everything they told me to do, and every year my eyes were a little worse" — isn't you being an exception. You're the rule that headline number quietly contains. The formula did something. It just never claimed to do everything — and somewhere along the way, that distinction got lost.
Your AREDS Formula Was Designed in 1996 — Around a Single Problem.
The approach sitting in your medicine cabinet traces back to research that began in the 1990s — and for its time, it was a real step forward. It was built to do one thing, and do it well: fight oxidative stress, the free-radical damage that wears on the macula, using antioxidants and zinc. Six core nutrients, one job.
That was the right answer for what was understood in 1996. The thing is, the research kept advancing — the protocol stayed the same. Three decades of work have since deepened how specialists think about why the macula declines, and what it needs to stay supported. The bottle didn't change. The understanding did.
None of this makes the old formula bad. It makes it incomplete — built for a narrower picture of the problem than the one we can see now. And once you've seen the fuller picture, it's hard to un-see the gap.
Macular Degeneration Has Three Root Causes. A Six-Ingredient Formula Was Built for One.
Modern understanding points to three root-cause pathways behind macular degeneration, not one. Oxidative stress is the first — and that's the pathway your AREDS formula was built around, so credit where it's due: that door is covered. But the macula also depends on the circulation that carries oxygen and nutrients up to it, and it depends on keeping the chronic inflammation that drives progression in check. A six-ingredient antioxidant-and-zinc formula was never designed for those last two.
Think of it plainly: AREDS locks the oxidative-stress door — and leaves the other two windows open.
Oxidative Damage
Free radicals attacking the macular pigment — the pathway AREDS was built to address.
Vitamin C, Vitamin E, Zinc, Copper, Lutein, Zeaxanthin, Vitamin A
Circulation Breakdown
Choroidal blood vessels lose flow capacity over time; the retina's photoreceptors literally starve.
Bilberry Extract, Grape Seed Extract, Niacin (B3), Rutin, Magnesium, Vitamin B1, Vitamin B12
Chronic Retinal Inflammation
A slow-burning oxidative cascade in retinal tissue, separate from the macular pigment.
Quercetin, Alpha Lipoic Acid, Lycopene, Eyebright, Selenium, Riboflavin
That's the whole gap, and it's not a knock on anyone. It's arithmetic. Six ingredients, aimed at one of three pathways. A formula can be excellent at the job it was given and still leave two-thirds of the picture unaddressed — because it was never asked to cover them. So the honest question isn't "is AREDS good?" It's the one you started with: is it enough? On the math alone, your current AREDS approach covers one of three root causes.
So that's where the math leaves you. Your current AREDS approach covers one of three root causes — the one it was built for in 1996 — while the circulation and inflammation pathways sit outside what six ingredients were ever meant to reach. Here's what those other two pathways actually need.
For a long time, that gap had no good answer. The AREDS core was the formula everyone was handed — and it was never built to reach the circulation and inflammation pathways. Closing that gap meant going back to the research: the decades of studies published since 1996 that mapped which specific nutrients support blood flow to the macula and help keep retinal inflammation in check.
That's exactly what Vision Enhance Pro was formulated to do. It keeps the proven AREDS antioxidant core — and adds the 18 additional nutrients the newer research points to, across all three root-cause pathways, in one daily capsule.
Essentially the AREDS foundation, plus the thirty years of research it never had.
Here's what that looks like:
